Please login to the form below

Not currently logged in
Email:
Password:

fostamatinib

This page shows the latest fostamatinib news and features for those working in and with pharma, biotech and healthcare.

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs

Rigel said it intends to launch Tavalisse (fostamatinib) in the US in May and - so far - hasn’t revealed what it intends to charge for the drug. ... Fostamatinib was being developed as a treatment for rheumatoid arthritis by AstraZeneca (AZ), but the

Latest news

  • Rigel shaken after fostamatinib misses phase III trial target Rigel shaken after fostamatinib misses phase III trial target

    Rigel shaken after fostamatinib misses phase III trial target. Firm will still pursue early 2017 FDA approval for the autoimmune disease therapy. ... In August, Rigel reported the same 18% response rate for fostamatinib in the FIT 1 trial.

  • Rigel plans job cuts in R&D restructure Rigel plans job cuts in R&D restructure

    Rigel plans job cuts in R&D restructure. Follows failure of fostamatinib disodium in rheumatoid arthritis trial. ... Rigel Pharmaceuticals plans to cut 30 jobs as part of a restructure of its research efforts following the failure of fostamatinib

  • Rigel on the slide as asthma drug falls over Rigel on the slide as asthma drug falls over

    The disappointment is another blow to the US firm after AstraZeneca (AZ) decided in June not to press ahead with a filing for rheumatoid arthritis candidate fostamatinib (R788) after taking a ... The fact that AZ also returned the rights to fostamatinib

  • AstraZeneca drops arthritis candidate fostamatinib AstraZeneca drops arthritis candidate fostamatinib

    AstraZeneca drops arthritis candidate fostamatinib. Hands rights back to Rigel after late-stage trial disappointment. ... Then, in April, fostamatinib missed one of two primary outcome measures in the OSKIRA-1 trial.

  • AstraZeneca's fostamatinib fails to match Humira in RA AstraZeneca's fostamatinib fails to match Humira in RA

    AstraZeneca's fostamatinib fails to match Humira in RA. Inferiority to Abbott’ s drug dents commercial prospects. ... AstraZeneca (AZ) suffered another pipeline setback after its rheumatoid arthritis (RA) candidate fostamatinib failed to meet

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics